Study Summary
This trial is testing TAR-200, a new immunotherapy drug, for bladder cancer. TAR-200 will be tested alone and in combination with cetrelimab, another immunotherapy drug, to see if it is effective in treating bladder cancer.
- Bladder Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
3 Treatment Groups
Cohort 1: TAR-200 and Cetrelimab
1 of 3
Cohort 3: Cetrelimab
1 of 3
Cohort 2: TAR-200
1 of 3
Experimental Treatment
200 Total Participants · 3 Treatment Groups
Primary Treatment: TAR-200 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is recruitment currently ongoing for this research?
"Based on information posted to clinicaltrials.gov, this trial is actively recruiting participants and was initially listed online on December 18th 2020; the entry has since been modified as recent as November 3rd 2022." - Anonymous Online Contributor
Are there numerous facilities offering this research study in the municipality?
"This trial is available at the University of Southern California in Los Angeles, Levine Cancer Institute in Charlotte, and Urologic Consultants of Southeastern Pennsylvania based in Bala-Cynwyd with 24 more sites spread around the United States." - Anonymous Online Contributor
What is the maximum number of participants that are being welcomed into this investigation?
"In order to successfully launch this trial, 200 individuals that meet the set criteria must participate. Potential subjects can find medical facilities offering the treatment in both Los Angeles, California and Charlotte North Carolina. Specifically, at University of Southern California and Levine Cancer Institute respectively." - Anonymous Online Contributor
Has the Food and Drug Administration (FDA) sanctioned TAR-200 for use?
"Contingent on the clinical evidence available, our team has assigned TAR-200 a safety index of 2. This is due to it being in its Phase 2 trial stage, hence there are some data points for safety but not yet any for efficacy." - Anonymous Online Contributor
To which ailments is TAR-200 typically prescribed?
"TAR-200 has been approved to manage small cell lung cancer (sclc) and can also be used for other carcinomas, such as head and neck, pancreatic adenocarcinoma locally advanced, and cervical cancers." - Anonymous Online Contributor
What are the major goals of this medical study?
"Over the course of up to 5 years, this trial will assess the Overall Clinical Response Rate. Secondary metrics for evaluation include Overall Survival (time from randomization to death), Change from Baseline in EORTC QLQ- Non-Muscle-Invasive Bladder Cancer 24 scores, and Number of Participants with Adverse Events by Severity Grades." - Anonymous Online Contributor
Could you elaborate on other empirical investigations conducted with TAR-200?
"Currently, there are 452 TAR-200 trials in progress, 134 of which have reached Phase 3. Among these studies, 25021 locations offer research opportunities for the drug with a concentration of them located in Woolloongabba, Queensland." - Anonymous Online Contributor